within Pharmacolibrary.Drugs.ATC.L;

model L04AC12
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.55,
    Cl             = 0.0045000000000000005,
    adminDuration  = 600,
    adminMass      = 0.21,
    adminCount     = 1,
    Vd             = 0.0039,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.004,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Brodalumab is a fully human monoclonal antibody targeting the interleukin-17 receptor A (IL-17RA). It is used primarily for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. The drug is approved in several countries, including the US, EU, and Japan, for this indication.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics in adult patients with moderate to severe plaque psoriasis. Data are primarily from healthy adults and patients aged 18-75 years. Parameters are reported following subcutaneous administration.</p><h4>References</h4><ol><li><p>Timmermann, S, &amp; Hall, A (2019). Population pharmacokinetics of brodalumab in patients with moderate to severe plaque psoriasis. <i>Basic &amp; clinical pharmacology &amp; toxicology</i> 125(1) 16–25. DOI:<a href=&quot;https://doi.org/10.1111/bcpt.13202&quot;>10.1111/bcpt.13202</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30661290/&quot;>https://pubmed.ncbi.nlm.nih.gov/30661290</a></p></li><li><p>Nakagawa, H, et al., &amp; Ootaki, K (2016). Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study. <i>Journal of dermatological science</i> 81(1) 44–52. DOI:<a href=&quot;https://doi.org/10.1016/j.jdermsci.2015.10.009&quot;>10.1016/j.jdermsci.2015.10.009</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26547109/&quot;>https://pubmed.ncbi.nlm.nih.gov/26547109</a></p></li><li><p>Salinger, DH, et al., &amp; Gibbs, MA (2014). A semi-mechanistic model to characterize the pharmacokinetics and pharmacodynamics of brodalumab in healthy volunteers and subjects with psoriasis in a first-in-human single ascending dose study. <i>Clinical pharmacology in drug development</i> 3(4) 276–283. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.103&quot;>10.1002/cpdd.103</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27128833/&quot;>https://pubmed.ncbi.nlm.nih.gov/27128833</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L04AC12;
